Investor Presentaiton
1H2023 Key Financials
Revenue
(RMB mm)
+3.2%
Gross Profit and Margin
39.5%
(RMB mm)
39.5%
Adjusted Net Profit Attributable to the Owners
of the Company and Margin (1)
(RMB mm)
24.4%
24.1%
+3.4%
+2.2%
3,594.2
3,710.9
1,418.3
1,466.3
876.5
895.6
1,422.1
1,607.5
617.6
640.8
2,172.1
2,103.4
800.7
825.5
1H2022
1H2023
Clinical trial solutions
Clinical-related and laboratory services
1H2022
1H2023
Clinical trial solutions
Clinical-related and laboratory services
1H2022
1H2023
●Tigermed (1) Non-IFRS measure. Adjusted for (i) share-based compensation expense, (ii) net foreign exchange loss/(gain), (iii) amortization of intangible assets arising from acquisitions, and (iv) changes in fair value of financial assets at FVTPL
4View entire presentation